| Medical and Health Sciences | Lifetime | 206 | US 112 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 200 | US 76 | 99.96 |
| Complementary and Alternative Medicine | Lifetime | 4 | US 1 | 99.95 |
| Cardiology and Cardiovascular Medicine | Lifetime | 67 | US 37 | 99.94 |
| Medical Physiology | Lifetime | 356 | US 202 | 99.42 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 671 | US 359 | 97.76 |
| Nutrition and Dietetics | Lifetime | 589 | US 244 | 97.35 |
| Clinical Pharmacology | Lifetime | 850 | US 360 | 96.02 |
| Rehabilitation | Lifetime | 785 | US 300 | 82.07 |
| Complementary and Alternative Medicine | 2021-2025 | 1 | US 1 | 99.84 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 76 | US 43 | 99.68 |
| Medical Physiology | 2021-2025 | 148 | US 52 | 98.22 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 155 | US 72 | 97.48 |
| Surgery | 2021-2025 | 578 | US 223 | 95.11 |
| Clinical Pharmacology | 2021-2025 | 259 | US 74 | 89.95 |
| Public, Environmental and Occupational Health | 2021-2025 | 929 | US 330 | 90.48 |
| Infectious Diseases | 2021-2025 | 851 | US 309 | 77.24 |
| Cardiovascular and exercise physiology | Lifetime | 3 | US 1 | 99.92 |
| Cardiac Health and Mental Health | Lifetime | 7 | US 4 | 99.88 |
| Heart Rate Variability and Autonomic Control | Lifetime | 13 | US 5 | 99.87 |
| Cardiovascular Disease and Adiposity | Lifetime | 12 | US 10 | 99.89 |
| Cardiovascular Function and Risk Factors | Lifetime | 28 | US 21 | 99.92 |
| COVID-19 Clinical Research Studies | Lifetime | 80 | US 23 | 99.46 |
| Cardiovascular Effects of Exercise | Lifetime | 27 | US 13 | 99.72 |
| Long-Term Effects of COVID-19 | Lifetime | 69 | US 19 | 99.08 |
| Physical Activity and Health | Lifetime | 45 | US 19 | 99.53 |
| COVID-19 and healthcare impacts | Lifetime | 119 | US 43 | 97.76 |
| Blood Pressure and Hypertension Studies | Lifetime | 201 | US 93 | 99.31 |
| Heart Failure Treatment and Management | Lifetime | 156 | US 82 | 99.38 |
| Cardiac Imaging and Diagnostics | Lifetime | 362 | US 198 | 99.40 |
| Obesity, Physical Activity, Diet | Lifetime | 289 | US 129 | 99.22 |
| Diet and metabolism studies | Lifetime | 509 | US 225 | 99.05 |
| Cardiovascular Health and Risk Factors | Lifetime | 73 | US 45 | 98.71 |
| Pharmacology and Obesity Treatment | Lifetime | 82 | US 44 | 98.84 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 332 | US 153 | 98.81 |
| Lipoproteins and Cardiovascular Health | Lifetime | 312 | US 165 | 98.63 |
| Fatty Acid Research and Health | Lifetime | 228 | US 94 | 98.08 |
| Acute Myocardial Infarction Research | Lifetime | 468 | US 213 | 98.58 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 584 | US 240 | 97.63 |
| Nutrition and Health in Aging | Lifetime | 917 | US 322 | 97.07 |
| Body Composition Measurement Techniques | Lifetime | 400 | US 149 | 96.33 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 834 | US 403 | 95.68 |
| Coffee research and impacts | Lifetime | 216 | US 43 | 93.91 |
| Vitamin C and Antioxidants Research | Lifetime | 547 | US 223 | 93.60 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 163 | US 55 | 92.46 |
| Sodium Intake and Health | Lifetime | 990 | US 392 | 87.60 |
| Genetics and Physical Performance | Lifetime | 550 | US 167 | 85.14 |
| Heart rate and cardiovascular health | Lifetime | 294 | US 96 | 84.45 |
| Cardiovascular and exercise physiology | 2021-2025 | 3 | US 1 | 99.73 |
| Cardiac Health and Mental Health | 2021-2025 | 5 | US 3 | 99.48 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 11 | US 3 | 99.41 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 143 | US 68 | 98.99 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 52 | US 17 | 97.10 |
| Cardiovascular Effects of Exercise | 2021-2025 | 62 | US 20 | 97.74 |
| Physical Activity and Health | 2021-2025 | 73 | US 10 | 97.91 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 256 | US 99 | 95.77 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 173 | US 49 | 95.25 |
| Heart Failure Treatment and Management | 2021-2025 | 271 | US 102 | 96.69 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 210 | US 74 | 95.66 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 56 | US 28 | 90.37 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 165 | US 89 | 92.85 |
| Diet and metabolism studies | 2021-2025 | 816 | US 246 | 93.09 |
| Pharmacology and Obesity Treatment | 2021-2025 | 80 | US 40 | 93.13 |
| Obesity, Physical Activity, Diet | 2021-2025 | 888 | US 227 | 92.78 |
| Fatty Acid Research and Health | 2021-2025 | 165 | US 45 | 89.65 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 981 | US 331 | 90.94 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 351 | US 70 | 86.73 |
| Diet, Metabolism, and Disease | 2021-2025 | 752 | US 127 | 83.97 |
| Estrogen and related hormone effects | 2021-2025 | 591 | US 188 | 77.58 |
| Coffee research and impacts | 2021-2025 | 479 | US 27 | 68.11 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 395 | US 69 | 64.08 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 558 | US 116 | 51.45 |
